4.090USD-0.73%Mkt Cap: 88.57M USDP/E: —Last update: 2026-06-01
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therape…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap88.57M USD
Enterprise Value-1.20M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.59M USD
Revenue/Share—
Last Price4.090 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.27
PEG—
EV/EBITDA0.02
EV/Revenue—
P/S—
P/B1.03
EPS (TTM)-3.21
EPS (Forward)-3.24
52W Range
3.3505% of range17.94
52W High17.94 USD
52W Low3.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.01%
ROA-49.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.17M USD
CapEx (TTM)95.00K USD
FCF Margin—
FCF Yield-38.88%
Net Debt-90.86M USD
Net Debt/EBITDA1.22
Balance Sheet
Debt/Equity0.00
Current Ratio8.06
Quick Ratio7.86
Book Value/Sh3.987 USD
Cash/Share4.180 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)15.44 USD
Target Range3.000 USD – 45.00 USD
# Analysts9
Ownership
Shares Out.21.82M
Float10.91M
Insiders16.15%
Institutions56.44%
Short Interest
Short Ratio6.0d
Short % Float7.03%
Short % Out.4.65%
Shares Short1.01M
Short (prev mo.)1.15M
Technical
SMA 504.767 (-14.2%)
SMA 2009.914 (-58.7%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)160.62K
Avg Vol (10d)237.95K
Technical Indicators
RSI (14)38.8
MACD-0.3473
MACD Signal-0.2116
MACD Hist.-0.1357
BB Upper6.804 USD
BB Middle5.061 USD
BB Lower3.319 USD
BB Width68.84%
ATR (14)0.5482 USD
Vol Ratio (20d)0.57x